Blood Cancer Drugs Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

The Business Research Company’s Blood Cancer Drugs Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

LONDON, GREATER LONDON, UK, March 15, 2022 /EINPresswire.com/ -- Companies in the blood cancer drugs market are increasingly investing in technologies such as artificial intelligence (AI) to save time and reduce research and development costs. AI is the simulation of human intelligence processes by machines, especially computer systems, which has the potential to surpass human intelligence levels. This technology helps to analyze large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. The technology also helps in speeding up the patient recruitment process by matching blood cancer patients with the most relevant clinical trials, thus lowering clinical trial costs. Major blood cancer drug manufacturers such as Roche, Pfizer and Johnson and Johnson have already invested in AI technologies to reduce time taken and costs incurred for drug development. For instance, Johnson and Johnson entered into an agreement with BenevolentAI, a UK-based artificial intelligence company (start-up), to mine data for designing new blood cancer drugs.

Read more on the Global Blood Cancer Drugs Market Report:
https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

The global blood cancer drugs market size is expected to grow from $54.83 billion in 2021 to $61.26 billion in 2022 at a compound annual growth rate (CAGR) of 11.7%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global blood cancer drugs market share is expected to reach $89.75 billion in 2026 at a CAGR of 10.0%.

The blood cancer drugs market growth is being driven by the growing death incidences and increasing prevalence of blood cancer cases across the globe. Different types of blood cancers such as lymphoma, leukemia, myeloma and others have different risk factors where some can be controlled or prevented through drug therapies and others may lead to death. According to Bristol-Myers Squibb Company report, over 1.85 million new blood cancer cases are expected to be diagnosed across the globe in 2040, out of which 918,872 cases are from lymphoma, 656,345 from leukemia, and 275,047 cases myeloma. Furthermore, the report estimated, in 2040, the approximate number of deaths worldwide due to blood cancer will be 1,100,000. According to the blood cancer drugs market forecast, the increasing deaths and increasing incidence of blood cancer cases globally drives the market.

Major players covered in the global blood cancer drugs industry are Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly, Johnson & Johnson, Novartis, Pfizer Inc, AbbVie Inc. and Takeda Pharmaceutical Company Ltd.

TBRC’s global blood cancer drugs market report is segmented by blood cancer type into leukemia, lymphoma, by drug into rituaxan/mabthera (rituximab), gleevac/glivec (imatinib), revlimid (lenalidomide), velcade (bortezomib), tasigna (nilotinib), pomalyst (pomalidomide), vidaza (azacitidine), kyprolis (carfilzomib), adcetris (brentuximab vedotin), others, by treatment approach into key findings, chemotherapeutic, mabs/targeted therapies, immunotherapeutic.

Blood Cancer Drugs Global Market Report 2022 – By Blood Cancer Type (Leukemia, Lymphoma), By Drugs (Rituaxan/Mabthera: Rituximab), Gleevac/Glivec: Imatinib), Revlimid: Lenalidomide), Velcade: Bortezomib), Tasigna: Nilotinib), Pomalyst: Pomalidomide), Vidaza: Azacitidine), Kyprolis: Carfilzomib), Adcetris: Brentuximab Vedotin)), By Treatment Approaches (Key Findings, Chemotherapeutic, Mabs/Targeted Therapies, Immunotherapeutic) – Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides a blood cancer drugs market overview, forecast blood cancer drugs market size and growth for the whole market, blood cancer drugs market segments, geographies, blood cancer drugs market trends, blood cancer drugs market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request for a Sample of the Global Blood Cancer Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2587&type=smp

Not what you were looking for? Here is a list of similar reports by The Business Research Company:
Blood And Blood Components Global Market Report 2022 – By Product (Whole Blood, Blood Components), By End-Users (Hospitals, Ambulatory Surgical Centers), By Application (Anemia, Trauma & Surgery, Cancer Treatment, Bleeding Disorders), By Blood Components (Red Blood Cells, Platelets, Plasma, White Blood Cells) – Market Size, Trends, And Global Forecast 2022-2026
https://www.thebusinessresearchcompany.com/report/blood-and-blood-components-global-market-report

Cancer Biologics Global Market Report 2022 – By Type (Monoclonal Antibodies, Vaccines, Cell And Gene Therapy), By Application (Non-Small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers), By Distribution Channel (Hospitals, Clinics) – Market Size, Trends, And Global Forecast 2022-2026
https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By Region, Opportunities And Strategies – Global Forecast To 2030
https://www.thebusinessresearchcompany.com/report/car-t-therapy-market

About The Business Research Company?
The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Check out our:
LinkedIn: https://bit.ly/3b7850r
Twitter: https://bit.ly/3b1rmjS
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: http://blog.tbrc.info/

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.